This retrospective study included nAMD patients whose eyes were grouped into the following cohorts, with the overall cohort receiving ≥ 1 brolucizumab injection; the 12-month and 18-month brolucizumab (BRO) cohorts, which consisted of nAMD patient eyes who switched from a previous anti-vascular endothelial growth factor (VEGF) and had ≥3 brolucizumab injections with no other anti-VEGF in the first 12 months (360 days) and 18 months (540 days) of follow-up respectively; and the 12-month and 18-month alternating (ALT) cohorts, which consisted of nAMD patient eyes who switched from a previous anti-VEGF to brolucizumab and had ≥2 brolucizumab injections and ≥1 injection of another anti-VEGF in the first 12 months and 18 months of follow-up, respectively.

Inclusion Criteria:

• Patients with a diagnosis of nAMD.
• Patients were on a previous anti-VEGF therapy and then switched to brolucizumab.
• Patients remained on brolucizumab for at least 12 months.
• Patients had exactly 360 days or more of follow-up after first brolucizumab injection.
• For BRO cohort only: Patients received at least three injections of brolucizumab during study period.
• For ALT cohort only: Patients received at least two injections of brolucizumab and one injection of another anti-VEGF during the study period.

Exclusion Criteria:

• For BRO cohort only: Patients who received any other anti-VEGF therapy during the 12-month follow-up period.
• Eyes missing bilaterality information in their nAMD diagnosis.
• Eyes missing bilaterality information in their brolucizumab injections.

This was a retrospective, noninterventional cohort study.